Safety and Efficacy of Peroxisome Proliferator-Activated Receptor-alpha Agonist for Treating Cardiovascular Disease.
10.4070/kcj.2007.37.12.599
- Author:
Young Ran KANG
1
;
Choong Hwan KWAK
;
Jin Yong HWANG
Author Information
1. Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea. jyhwang@gnu.ac.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
PPAR-alpha;
Fibrates;
Safety
- MeSH:
Biology;
Cardiovascular Diseases*;
Fibric Acids;
Homeostasis;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Lipid Metabolism;
Metabolism;
Mortality;
Nuclear Family;
Peroxisome Proliferator-Activated Receptors;
Peroxisomes*;
Triglycerides
- From:Korean Circulation Journal
2007;37(12):599-608
- CountryRepublic of Korea
- Language:English
-
Abstract:
Peroxisome proliferator-activated receptor (PPAR)-alpha belongs to the nuclear family of ligand-activated transcriptional factors. The main role of PPAR-alpha is to activate the expression of the genes that are involved in fatty acid oxidation to achieve energy homeostasis. Fibrates are a known class of PPAR-alpha agonists, and they been used clinically for their effects of lowering triglycerides and elevating high-density lipoprotein-cholesterol (HDL-C). Further, recent experimental studies have demonstrated the anti-inflammatory and anti-atherosclerotic actions of PPAR-alpha agonists directly on the vascular wall. PPAR agonists are currently emerging as a promising therapeutic option to control systemic and vascular atherogenic factors. Regardless of their strong anti-atherosclerotic properties, large clinical studies have demonstrated inconsistent results for the cardioprotective effect of PPAR-alpha agonists; moreover, it has been observed that they did not decrease the total mortality, which stands in contrast to the statin trials. This review summarizes the current knowledge regarding the PPAR biology and the mechanisms of the effects of PPAR-alpha on lipid metabolism, the vessel wall and the cardiac metabolism. We also describe the results and lessons learned from the important clinical trials of PPAR-alpha agonists and we discuss these drugs' efficacy and safety.
